You are here

Article Text

Article menu

Download PDFPDF

Poster Presentations
P149 Clinical worsening in non-adherent belimumab treatment in SLE
  1. Marta de la Rubia Navarro1,
  2. Elena Grau García2,
  3. Ma Jesús Cuellar Monreal3,
  4. Iago Alcántara Álvarez1,
  5. Inmaculada Chalmeta Verdejo1,
  6. Hikmat Charia2,
  7. Luis González Puig1,
  8. Anderson Víctor Huaylla Quispe1,
  9. José Ivorra Cortés1,
  10. Samuel Leal2,
  11. Isabel Martínez Cordellat1,
  12. Laura Mas Sánchez1,
  13. Pablo Francisco Muñoz Martínez1,
  14. Rosa Negueroles Albuixech1,
  15. José Eloy Oller Rodríguez1,
  16. Daniel Ramos Castro1,
  17. Carmen Riesco Bárcena1,
  18. Alba Torrat Novés1,
  19. Ernesto Tovar Sugrañes1,
  20. Elvira Vicens Bernabeu1,
  21. Belén Villanueva Mañes1,
  22. Inés Cánovas Olmos1,
  23. Carmen Nájera Herranz1 and
  24. José Andrés Román Ivorra1
  1. 1Rheumatology Dept., HUP La Fe, Valencia, Spain
  2. 2Rheumatology Dept., Instituto de Investigación Sanitaria La Fe, HUP La Fe, Valencia, Spain
  3. 3Pharmacy Dept., HUP La Fe, Valencia, Spain

Abstract

Objective The objective is to analyze the association between therapeutic adherence and disease activity in SLE patients.

Methods An observational, prospective study in SLE patients (SLICC/ACR criteria), treated whit subcutaneous Belimumab (200 mg/week) was made. Disease activity was measured by SLEDAI in three consecutive visits, and it was considered clinical worsening an increase of SLEDAI-score of ≥4 point. Persistence and adherence of Belimumab data during the follow-up were collected and were calculated based on the number of drug dispensing. Poor therapeutic adherence was established under the 95%.

Results Thirty-one prescriptions of Belimumab were registered (83.9% women) with a mean age of 48.1 (14.9) years. Time since the diagnosis was 12.5 (6.29) years and treatment period were 2.2 (1.4) years. Fifteen patients were considered as non-adherent (48.4%).

Persistence and disease activity data in each group were showed in the table 1.

View this table:
Abstract P149 Table 1

Poor adherence was secondary to clinical improvement (66.67%), recurrent infections (13.33%), surgery (6.67%), pregnancy (6.67%) and inability to drug collect due to COVID-19 pandemic (6.67%). Non-adherent group showed worse SLEDAI-score than adherent group in V0, despite of a similar SLEDAI-score at V2 in both groups was observed. There was an association between poor therapeutic adherence and high delta_SLEDAI (p=0.046).

Conclusions We observed an association between poor therapeutic adherence and delta_SLEDAI. The high SLEDAI-score at the beginning of the study in non-adherent group would be due to clinical manifestations, despite of the similar serological activity in both groups.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ .

https://doi.org/10.1136/lupus-2024-el.203

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.